Contenidos recomendados por condep1002

condep1002 25/05/16 07:11

Ha respondido al tema Farmas USA

http://www.capitalcube.com/blog/index.php/etfs-with-exposure-to-novavax-inc-may-24-2016/

condep1002 24/05/16 20:44

Ha respondido al tema Farmas USA

http://247wallst.com/healthcare-business/2016/05/23/10-speculative-biotech-and-biohealth-stocks-with-massive-analyst-upside-calls/ Amarin Amarin Corp. (NASDAQ: AMRN) was assumed with a Buy rating and a $3.50 price target (versus a $1.57 prior close) at Jefferies on May 12. The firm said it believes that the off-label Vascepa promotion in mixed dyslipidemia may be starting to bear fruit. It said: We believe off-label Vascepa promotion in mixed dyslipidemia may be beginning to bear fruit, where our analysis of TRx data suggests a steeper upward trend in recent months v. 2015. Access to this population is a major source of upside, where we see opportunity of $2.5 billion. Focus is also on REDUCE-IT where we believe Vascepa can show a benefit on final analysis in early 2018, and upside could be $14 per share. Read more: 10 Speculative Biotech and Biohealth Stocks With Massive Analyst Upside Calls - Amarin Corp plc (ADR) (NASDAQ:AMRN) - 24/7 Wall St. http://247wallst.com/healthcare-business/2016/05/23/10-speculative-biotech-and-biohealth-stocks-with-massive-analyst-upside-calls/#ixzz49bHOVIGF Follow us: @247wallst on Twitter | 247wallst on Facebook

condep1002 10/05/16 10:54

Ha respondido al tema Farmas USA

http://www.smarteranalyst.com/2016/05/06/h-c-wainwright-reiterates-buy-amarin-corporation-plc-adr-following-1q16-update/ http://www.marketbeat.com/stocks/NASDAQ/AMRN/ 5/9/2016 HC Wainwright Reiterated Rating Buy $10.00

condep1002 28/12/15 16:39

Ha respondido al tema Farmas USA

Goldman & Company boosted its stake in shares of Amarin Co. plc (NASDAQ:AMRN) by 321.2% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The hedge fund owned 1,282,306 shares of the biopharmaceutical company’s stock after buying an additional 977,861 shares during the period. J. Goldman & Company’s holdings in Amarin Co. plc were worth $2,475,000 at the end of the most recent quarter

condep1002 01/12/15 23:28

Ha respondido al tema Farmas USA

original Traders are looking for Amarin to rally in coming weeks. optionMONSTER's Heat Seeker monitoring system detected the purchase of more than 7,000 December 2.50 calls for $0.03 to $0.06 today. Volume surpassed open interest of 1,530 contracts, an indication that new money was put to work. Long calls lock in the price where investors can buy stock, allowing them to profit from a rally with limited capital at risk. Their cheap cost can also generate significant leverage on a percentage basis if shares move in the right direction. (See our Coaching section) AMRN is down 1.18 percent to $2.09 in afternoon trading but is up 8 percent in the last month. The heart-drug maker has missed revenue forecasts for the last several quarters, most recently on Nov. 4. The next set of numbers are estimated for pre-market hours on March 3. Overall option volume was 15 times greater than average, according to Heat Seeker. Calls outnumbered puts by a bullish 7-to-1 ratio. By optionMONSTER Staff (media-support-team@optionmonster.com) November 30, 2015 3:25 PM

condep1002 30/11/15 17:44

Ha respondido al tema Farmas USA

ampliación de la original November 30, 2015 at 08:00 AM EST Chiasma Announces Addition of James R. Tobin and John F. Thero to Board of Directors NEWTON, Mass., Nov. 30, 2015 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a late-stage biopharmaceutical company developing Mycapssa™ (octreotide capsules), an investigational oral drug for the maintenance therapy of adult patients with the orphan disease acromegaly, today announced that James R. Tobin and John F. Thero have joined the company's Board of Directors. Mr. Tobin, formerly president and CEO of Biogen, Inc. and Boston Scientific Corporation, will serve as a member of the Audit Committee. Mr. Thero, President and CEO of Amarin Corporation (NASDAQ:AMRN), will serve as chairman of the Audit Committee. "We are excited to add these experienced, highly regarded biotech leaders to Chiasma's Board of Directors at this important stage in our development," said Mark Leuchtenberger, Chief Executive Officer of Chiasma. "Both Jim and John have deep operational and commercial experience on an international level, and their business acumen and leadership will be invaluable to the Board as we continue to build out our infrastructure and position the company for long-term success." Mr. Tobin was most recently President and CEO of Boston Scientific Corporation from March 1999 to July 2009. Prior to Boston Scientific, he served as President and CEO of Biogen from February 1997 to December 1998, and President and COO of Biogen from February 1994 to February 1997. Prior to joining Biogen, Mr. Tobin was with Baxter International Inc., where he served as President and COO from 1992 to 1994, as Executive Vice President from 1988 to 1992, and in various management positions prior to 1988. Mr. Tobin served as lieutenant in the U.S. Navy from 1968 to 1972. He has been a Director of multiple private and public life science firms and hospitals, and currently serves on the boards of several private companies as well as Globus Medical, Inc. (NYSE:GMED) and Oxford Immunotec Global PLC (NASDAQ:OXFD). Mr. Tobin earned an M.B.A. from Harvard Business School and an A.B. from Harvard College. Mr. Thero joined Amarin in November 2009 and has more than 20 years of senior financial and operational management experience, including more than 15 years supporting the growth of life science companies. Mr. Thero became President and CEO of Amarin in 2014 after previously serving as the company's President and initially as the company's Chief Financial Officer. Prior to Amarin, Mr. Thero was at ViaCell, Inc., where as Chief Financial Officer he helped guide the company to its successful sale to PerkinElmer, and Abiomed, Inc., where he held multiple positions, including Senior Vice President of Business Operations and Chief Financial Officer, and helped manage the company's transition from a development-stage company into a commercial entity. Mr. Thero began his professional career at Arthur Andersen LLP.

condep1002 30/11/15 17:27

Ha respondido al tema Farmas USA

uno original NEWTON, Mass., Nov. 30, 2015 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a late-stage biopharmaceutical company developing Mycapssa™ (octreotide capsules), an investigational oral drug for the maintenance therapy of adult patients with the orphan disease acromegaly, today announced that James R. Tobin and John F. Thero have joined the company's Board of Directors. Mr. Tobin, formerly president and CEO of Biogen, Inc. and Boston Scientific Corporation, will serve as a member of the Audit Committee. Mr. Thero, President and CEO of Amarin Corporation (NASDAQ:AMRN), will serve as chairman of the Audit Committee.

condep1002 30/11/15 10:10

Ha respondido al tema Farmas USA

Algunos dicen que compararon niveles de epa de una población occidental a una población de mujeres posmenopáusicas japonesas crea incertidumbre acerca de los efectos significativos de reducir-It. El argumento contrario es que aunque una química diferente existe en personas de edad avanzada las mujeres japonesas, son seres humanos con hábitos muy saludables, por lo que cualquier ayuda en la reducción de eventos adversos del corazón también es notable en la parte superior del statin, (21% del total de pop, 50% de subgrupos que se asemejan a R-It). No podría significar nada, pero cuando el estudio de cerezo, acaba de publicar, muestra realmente lo que está sucediendo dentro de las arterias en un corto periodo de tiempo, (reducción de la placa del 15%), se convierte en algo obvio Vascepa podría funcionar. Y que realmente deben cumplir los criterios originales necesarios para la aprobación de anclaje. Ciertos estudios también menciona que la estatina involucrada en reducir-It está mucho más fuerte. Que es verdad y crea cierta duda, pero Vascepa parece multiplicar los efectos beneficiosos y hay 2 x la cantidad de epa en el estudio vs JELIS. También es el argumento de placebo que puedan impactar las cifras de lípidos... PERO, al final lo único que realmente importa es lo que muestran los resultados de reducir-It. Si hay una gran disminución de enfermedades cardiovasculares y las cifras de lípidos y el efecto placebo no significan tanto, (que significan mucho pero comparado con la muerte, quiero decir...). Si epa actúa la manera que hemos visto en muchos estudios, la evaluación de término más largo de la droga también podría revelar lo siguiente: menos dolor en las articulaciones, mejor cognición, mejor por todas las causas mortalidad, menos casos de cáncer, menos trazos, mejor estado de ánimo y sin efectos secundarios graves. la acción subira. ¿cuando ? no soy adivino, los de las carteras grandes se estan moviendo.

condep1002 06/11/15 15:03

Ha respondido al tema Farmas USA

Lo único objetivo; son las ventas ; y la deuda; lo demás son pura especulación; no obstante considero que los que manejan la información que son los mismos de siempre; especularan con la acción; a su conveniencia; y si saben algo cargaran su saco y cuando menos te lo esperes saltara la noticia.... a la larga pienso que la empresa tendrá beneficios....pero hay amigo quien es el que estará dentro en el momento adecuado eso para algunos como yo será por intuición; para los de las carteras grandes; que ya lo sabrán mucho antes será simplemente una de tantas donde juegan con las cartas marcadas; porque manejan la información; mi intuición : a la larga repito la empresa tendrá beneficios; pero ojo, que hay que saber manejar bien las situaciones que se producirán. ¿Quién aguantara?. ¿Quién estará en el momento adecuado?. La paciencia es una virtud.

condep1002 30/10/15 13:23

Ha respondido al tema Farmas USA

Algunos que son los que manejan la información saben que este valor con el tiempo les reportara buenos beneficios y que subira el doble; pero ahora lo que les interesa es cargar el zurrón, luego la bajaran ya lo veréis, y cuando tengan las que consideren oportunas, cerraran el ciclo, y para arriba como un cohete; cuando a los demás les pille con el pie cambiado, Quien quiere jugar esta partida de poker. AMRN